Discovery of Non-racemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders.

Please login or register to bookmark this article
Bookmark this %label%

In contrast to the dose-occupancy relationship in the treatment of schizophrenia, the minimal effective level of dopamine receptor 2 (D2R) blockade for antipsychotics in the treatment of bipolar depression is unknown. Lower doses aimed at relieving extrapyramidal side effects are balanced against retaining D2R benefit on emergent cycling, mixed, manic, anxiety and/or psychotic symptoms. Dose-reductions intended to lower D2R blockade however could also decrease concomitant serotonin receptor antagonism and its potential benefit on depressive symptoms. Here we uncoupled the potential antidepressant activity in amisulpride, driven by 5-HT7 receptor (5-HT7R) antagonism, from the D2R-mediated antipsychotic activity by discovering that each enantiomer favors a different receptor. Aramisulpride was more-potent at 5-HT7R relative to esamisulpride (Ki 47 vs 1,900 nM, respectively), while esamisulpride was more potent at D2R (4.0 vs 140 nM). We hypothesized that a non-racemic ratio might achieve greater 5-HT7R-mediated antidepressant effects at a lower level of D2R blockade. The dose-occupancy relationship of esamisulpride at D2R was determined by PET imaging in human volunteers. Separately the dose-relationship of aramisulpride was established in humans using suppression of rapid eye movement (REM) sleep as a marker of 5-HT7R antagonism. These results led to the discovery of an 85:15 ratio of aramisulpride to esamisulpride (SEP-4199) that maximizes the potential for antidepressant benefit of aramisulpride via 5-HT7R and reduces esamisulpride to minimize D2R-related extrapyramidal side effects while still retaining D2R-mediated effects predicted to provide benefit in bipolar depression. SEP-4199 was recently evaluated in a proof of concept trial for the treatment of bipolar depression (NCT03543410).

View the full article @ Clinical pharmacology and therapeutics
Get PDF with LibKey

Authors: Seth C Hopkins, Scott Wilkinson, Taryn J Corriveau, Hiroyuki Nishikawa, Keiko Nakamichi, Antony Loebel, Kenneth S Koblan